131 related articles for article (PubMed ID: 37861205)
21. Screening for ovarian cancer in the general population.
Gentry-Maharaj A; Menon U
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
23. Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research.
Gadducci A; Cosio S
Anticancer Res; 2022 Sep; 42(9):4207-4216. PubMed ID: 36039417
[TBL] [Abstract][Full Text] [Related]
24. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
25. Early Detection of Ovarian Cancer.
Elias KM; Guo J; Bast RC
Hematol Oncol Clin North Am; 2018 Dec; 32(6):903-914. PubMed ID: 30390764
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
27. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
28. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer screening: Current status and future directions.
Nash Z; Menon U
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():32-45. PubMed ID: 32273169
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer screening in the high-risk population--the UK Familial Ovarian Cancer Screening Study (UKFOCSS).
Rosenthal AN
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S27-8. PubMed ID: 22543917
[No Abstract] [Full Text] [Related]
32. Ovarian cancer detection by DNA methylation in cervical scrapings.
Wu TI; Huang RL; Su PH; Mao SP; Wu CH; Lai HC
Clin Epigenetics; 2019 Nov; 11(1):166. PubMed ID: 31775891
[TBL] [Abstract][Full Text] [Related]
33. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.
Chang CC; Wang HC; Liao YP; Chen YC; Weng YC; Yu MH; Lai HC
J Gynecol Oncol; 2018 Jan; 29(1):e17. PubMed ID: 29185275
[TBL] [Abstract][Full Text] [Related]
34. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
Cohen PA; Flowers N; Tong S; Hannan N; Pertile MD; Hui L
BMC Med; 2016 Aug; 14(1):126. PubMed ID: 27558279
[TBL] [Abstract][Full Text] [Related]
35. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer.
Dong R; Yu J; Pu H; Zhang Z; Xu X
J Int Med Res; 2012; 40(2):681-6. PubMed ID: 22613430
[TBL] [Abstract][Full Text] [Related]
36. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
[TBL] [Abstract][Full Text] [Related]
37. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
39. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
40. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]